Form 4: Myriad Genetics Director Daniel K. Spiegelman Reports Departure in SEC Filing
SEC Form 4 Filing
Daniel K. Spiegelman, a director at Myriad Genetics, filed a Form 4 with the SEC to report his departure from the company, effective June 6, 2024.
Summary
- Daniel K. Spiegelman, a director at Myriad Genetics Inc. (MYGN), has ceased serving as a director, effective June 6, 2024.
- He filed a Form 4 with the SEC to report this change in his role.
- The filing indicates that he beneficially owns 32,917 shares of Myriad Genetics common stock.
- This Form 4 is voluntarily filed to report that the Reporting Person is no longer serving in the role as a director of the Company, effective June 6, 2024, and therefore is no longer subject to Section 16 reporting.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding a director's departure. It doesn't contain information that would significantly impact investor sentiment positively or negatively.
Industry Context
Director departures are a normal part of corporate governance. The impact on Myriad Genetics will depend on the circumstances of the departure and the company's succession plan.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Daniel K. Spiegelman | 06/06/2024 | Departure from the company |
Stakeholder Impact
- Shareholders may be interested in the reasons for the director's departure.
- The company will need to consider filling the vacant director position.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Effective date of Daniel K. Spiegelman's departure as a director. |
| 06/07/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.